Review of mitoxantrone in the treatment of multiple sclerosis

Neurology

Volumn 63, Issue 12 SUPPL. 6, 2004, Pages

  Jeffery, Douglas R ^a   Herndon, Robert ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; PLACEBO;

ALLERGIC ENCEPHALOMYELITIS; ALOPECIA; AMENORRHEA; CARDIOTOXICITY; CONFERENCE PAPER; DISABILITY; DRUG EFFICACY; FATIGUE; FETUS MALFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INFERTILITY; LEUKEMIA; MULTIPLE SCLEROSIS; NAIL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SCLERA DISEASE; SYSTEMATIC REVIEW;

EID: 10944258663     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.12_suppl_6.s19     Document Type: Conference Paper

References (29)

1. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986;137:727-732.
2. Fidler JM, DeJoy SQ, Smith FR III, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986;136:2747-2754.
3. Levine S, Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. Int J Immunopharmacol 1986;8:999-1007.
4. Ridge SC, Sloboda AE, McReynolds RA, et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985;35:35-42.
5. Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986;13:175-181.
6. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987;45:122-128.
7. Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991;13:923-930.
8. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
9. Goodkin DE, and the North American Study Group on Interferon beta1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000;54:2352. Abstract.
10. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001;56:1496-1504.
11. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
12. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-918.
13. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-446.
14. Likosky WH, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991;54:1055-1060.
15. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8:142-154.
16. Perini P, Calabrese F, Ranzato F, Gallo P. The immunosuppression (IS) responsive secondary progressive MS. Experience from cyclophosphamide and mitoxantrone treated SPMS indicates the clinical profile of the IS candidate patient. J Neurol 2004;251(suppl 3):459. Abstract.
17. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-1406.
18. Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990;40:261. Abstract.
19. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.
20. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
21. van de Wyngaert FA, Beguin C, D'Hooghe MB, et al. Acta Neurol Belg 2001;101:210-216.
22. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287.
23. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
24. Jeffery DR, Lefkowitz DS, Critlenden JP. Treatment of Marburg variant multiple sclerosis with mitoxantrone. J Neuroimaging 2004;14:58-62.
25. Novantrone [package insert]. Rockland, MA: Serono Inc., 2003.
26. Rose JW. Mitoxantrone-related toxicity in multiple sclerosis. Neurology 2002;59:795-797.
27. Smith CH, Lopez-Bresnahan MV, Beagan J. Safety and tolerability of Novantrone® (mitoxantrone) in clinical practice: Status report from the Registry to Evaluate Novantrone® Effects in Worsening MS (RENEW) Study. Neurology 2004;62(suppl 5):A489. Abstract.
28. Edan G, Brochet B, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Neurology 2004;62(suppl 5):A493. Abstract.
29. Jeffery DR. Pilot trial of combined therapy of IFNb-1b and mitoxantrone in the treatment of MS using monthly MRI. Neurology 2002;59:1-8. Abstract.